Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.
Ahmadi P, Alsdorf W, Leypoldt L, Kosch R, Schaefers C, Gagelmann N, Ayuk F, Kron F, Weisel K. Ahmadi P, et al. Among authors: weisel k. Bone Marrow Transplant. 2025 Jan 22. doi: 10.1038/s41409-024-02505-x. Online ahead of print. Bone Marrow Transplant. 2025. PMID: 39843583 No abstract available.
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Moreau P, et al. Among authors: weisel k. Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02506-1. Online ahead of print. Leukemia. 2025. PMID: 39815052
Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up of the Phase 3 GMMG ReLApsE Trial.
Baertsch MA, Schlenzka J, Hielscher T, Raab MS, Sauer S, Merz M, Mai EK, Müller-Tidow C, Luntz S, Jauch A, Brossart P, Goerner M, Klein S, Glass B, Reimer P, Graeven U, Fenk R, Haenel M, von Metzler I, Lindemann HW, Scheid C, Blau IW, Salwender HJ, Noppeney R, Besemer B, Weisel KC, Goldschmidt H. Baertsch MA, et al. Among authors: weisel kc. Blood. 2025 Jan 14:blood.2024027342. doi: 10.1182/blood.2024027342. Online ahead of print. Blood. 2025. PMID: 39808798
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.
Richardson P, Beksaç M, Oriol A, Lindsay J, Schjesvold F, Galli M, Yağcı M, Larocca A, Weisel K, Yu X, Donahue C, Acosta J, Peluso T, Dimopoulos M. Richardson P, et al. Among authors: weisel k. Eur J Haematol. 2025 Jan 8. doi: 10.1111/ejh.14365. Online ahead of print. Eur J Haematol. 2025. PMID: 39777934
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.
Oelschläger L, Künstner A, Frey F, Leitner T, Leypoldt L, Reimer N, Gebauer N, Bastian L, Weisel K, Sailer VW, Röcken C, Klapper W, Konukiewitz B, Murga Penas EM, Forster M, Schub N, Ahmed HMM, Kirfel J, von Bubnoff NCC, Busch H, Khandanpour C. Oelschläger L, et al. Among authors: weisel k. Int J Mol Sci. 2024 Dec 14;25(24):13418. doi: 10.3390/ijms252413418. Int J Mol Sci. 2024. PMID: 39769182 Free PMC article.
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, Shune L, Isufi I, Harrison SJ, Shah UA, Schecter JM, Vogel M, Lendvai N, Gries KS, Katz EG, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho OC, Patel N, Florendo E, Karlin L, Weisel K. Mina R, et al. Among authors: weisel k. Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X. Lancet Haematol. 2025. PMID: 39756844 Clinical Trial.
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Mai EK, et al. Among authors: weisel kc. J Clin Oncol. 2024 Dec 9:JCO2402266. doi: 10.1200/JCO-24-02266. Online ahead of print. J Clin Oncol. 2024. PMID: 39652594
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies.
Diamond B, Chahar D, Jain MD, Poos AM, Durante M, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan K, Jelinek T, Davies F, Figura NB, Morgan G, Mai E, Weisel KC, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Diamond B, et al. Among authors: weisel kc. bioRxiv [Preprint]. 2024 Nov 18:2024.11.15.623836. doi: 10.1101/2024.11.15.623836. bioRxiv. 2024. PMID: 39605649 Free PMC article. Preprint.
314 results